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Background: Experimental models of pneumonia with penicillin non-susceptible Streptococcus pneumoniae (PNSSP)
are hard to reproduce because the majority of strains with clinical relevance (like serotypes 6B, 9 V and 19 F) have
low murine virulence. By optimization of culture and inoculum conditions of PNSSP (using porcine mucin), our aim
was to develop a suitable, reliable and reproducible pneumonia mouse model for anti-infective pharmacology
research.
Results: Seven PNSSP strains, including serotypes 6B, 9 V, 14 and 19 F were included. Strain INS-E611 displayed
the highest murine virulence and was chosen to validate the lung model. Nose-instilled pneumococci grew
between 2.1 and 2.5 log10 CFU/g of lung in 24 hours when an optimized culture of bacterial cells was used,
but animals were all alive and recovered of infection after 36 h. In contrast, inoculum supplementation with
mucin led to 100% mortality related to a successful lung infection confirmed by histopathology. These findings
were reproduced with all seven PNSSP strains in neutropenic mice. Immunocompetent animals cleared all
strains spontaneously.
Conclusions: This pneumonia model produces a progressive and uniformly fatal lung infection with diverse
serotypes of PNSSP independently of their intrinsic murine virulence.
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Streptococcus pneumoniae is a leading cause of infection
in young children, the elderly and debilitated patients.
Its spectrum of disease ranges from otitis media and si-
nusitis to life-threatening infections such as pneumonia
and meningitis that kill every year almost one million
children younger than 5 year-old [1]. A fully susceptible
microorganism in the past, S. pneumoniae treatment
options are currently endangered by the emergence
and dissemination of multiple drug resistance (MDR),
especially to β-lactams, macrolides and quinolones [2].
Despite massive, highly effective vaccination, S. pneumoniae* Correspondence: omar.vesga@udea.edu.co
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creativecommons.org/publicdomain/zero/1.0/is still very able to cause serious disease through those sero-
types not included in the diverse polyvalent vaccines [3,4].
Animal models of human lung infection are essential
tools for the preclinical testing and optimization of new
drugs and vaccines, dose regimens and antibiotic combi-
nations [5,6]. In the case of penicillin non-susceptible
Streptococcus pneumoniae (PNSSP), the majority of strains
of clinical importance (like serotypes 6B, 9 V and 19 F)
have low virulence for mice [7-9]; as a natural conse-
quence of this experimental limitation, published models
of murine pneumococcal pneumonia are difficult to repro-
duce [10,11]. To increase the probability of inducing
pneumonia, the microorganism is delivered by unnatural
routes like intratracheal injection, which is technically dif-
ficult, time-consuming, traumatic, and leads to asymmet-
ric deposition of microorganisms with high variance [10].
A natural method of delivery, like the aerosolization of thearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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menter, requires expensive equipment, and does not lead
to success with strains without murine virulence [12]. An
important disadvantage noted in the literature is that
bacterial growth is either not determined [13] or poor
(<1 log10 CFU/g of lung tissue) [14], and the intra- and
inter-experimental variance is usually high [12], minimiz-
ing its relevance [15]. In consequence, available PNSSP
pneumonia models are characterized by their lack of
reliability, a severe hindrance to assess the efficacy of
antibiotics against the many serotypes of this important
human pathogen [12,16].
Here, by optimization of culture and inoculum conditions
of PNSSP, our aim was to develop a suitable, reliable and
reproducible pneumonia mouse model for anti-infective
pharmacology research. The initial data of this work
were presented at the 45th Interscience Conference on
Antimicrobial Agents and Chemotherapy.Methods
Bacterial strains, supplementation and optimization of
in vitro conditions
We studied two clinical strains of penicillin-resistant
(INS-E611, E674) Streptococcus pneumoniae and five
penicillin-intermediate isolates (E676, E678, E683, E684
and ATCC 49619), all of them provided by the Colom-
bian National Institute of Health (Instituto Nacional de
Salud, Bogotá, Colombia). The minimal inhibitory and
bactericidal concentrations of these strains to several
drugs were previously published [17], including also the
capsular serotypes 6B (INS-E611), 9V (INS-E683), 14
(INS-E674, INS-676, INS-678, INS-684) and 19 F
(ATCC 49619). Microorganisms were stored at −70°C
using skim milk media (Becton Dickinson & Co. Sparks,
MD, USA). The standardization of the optimal culture
conditions of pneumococci to produce ≥9 log10 CFU/mL
of early log-phased cells without autolysis was described
elsewhere [17]. Briefly, cells from frozen stock were
recovered by two successive passages on solid media (5%
sheep blood Trypticase soy agar supplemented with
0.5% yeast extract) incubated during 15 hours (h) under
5% CO2 atmosphere at 37°C. Then, 10 colonies from the
second passage were diluted in 10 mL of Todd Hewitt
Broth (THB, Becton Dickinson & Co, Sparks, MD, USA)
supplemented with 2.5% horse blood and 2% yeast ex-
tract (adjusting pH to 7.8) and incubated during 12 h
under a 5% CO2 atmosphere at 37°C. Finally, 1 mL of the
bacterial suspension was diluted again in 9 mL of supple-
mented THB and incubated under the same atmosphere
during 4 to 5 h (early-log phase) until obtaining an
O.D580nm of 0.8 that, according to previous standardization
procedures, corresponds to a final inoculum of ~8 log10
cells per mL, ready for in vivo experiments.Animals
Six week old, murine pathogen free mice from the our
strain Udea:ICR(CD-1) [18], weighing 23–27 g, were
used in all experiments, including females for the pneu-
monia model and males for assays of pneumococcal
virulence. All animals were given food and water ad
libitum and the study was approved by the University of
Antioquia Animal Care and Experimentation Ethics
Committee. Mice were rendered neutropenic (<100 neutro-
phils/μL) by two intraperitoneal injections of cyclophospha-
mide (Cytoxan®, BMS, Princeton, NJ) 4 days (150 mg/kg)
and 1 day (100 mg/kg) before infection [19].
In vivo assays of pneumococcal virulence
Groups of at least 2 immunocompetent male mice were
inoculated with each strain in both thighs with 0.1 mL
of a bacterial suspension having ~8 log10 CFU/mL. After
26 h, mice were euthanized and thighs, lungs, liver, kid-
ney and spleen were aseptically removed, homogenized
and cultured on 5% sheep blood trypticase soy agar dur-
ing 18 h under 5% CO2 at 37°C for bacterial counting.
Five colonies of each strain were selected from the solid
media to be used in up two additional cycles of the same
animal model. To describe the clinical findings observed
in infected animals during thigh passages, we designed
the following score of murine virulence: 4+ (the mice
died during the assay), 3+ (mice ended alive but with
systemic illness), 2+ (mice with localized sickness) and
1+ (mice without clinical signs of disease). The objective
of this step was to maximize the probability of success
in our first attempts by selecting the penicillin non-
susceptible strain with the highest virulence (i.e. a strain
that induces lethality and dissemination to distant or-
gans) for the development of the pneumonia model
without the addition of porcine mucin. Subsequent ex-
periments did not include thigh passages.
Induction of pneumonia in mice
Before infection, female neutropenic mice were anesthe-
tized by a subcutaneous injection (100 μL) of 100 mg/kg
of ketamine (Ketalar®, Parke-Davis, Ecuador) plus
10 mg/kg of xylazine (Rompun®, Bayer S.A, Brazil), and
the eyes were rubbed with Viscotears® (Dr. G. Mann
Pharma) to prevent corneal ulcerations. Each mouse was
inoculated by intranasal instillation with 50 μL of a bac-
terial suspension containing ~8 log10 CFU/mL. After in-
stillation, animals were held in a vertical position during
10 min hanging from their incisor teeth to favor migra-
tion of bacteria to the alveoli by gravity. A minimum of
three mice per experimental group were sacrificed in at
least three of the following time-points: 0, 1, 6, 12, 18,
24, 32, 36, 38, 40 and 48 h post-infection (experiments
were performed at least twice to test repeatability); in
addition, a minimum of four animals were observed
Table 1 Capsular serotypes, antibiotic susceptibility
patterns and in vivo virulence of the seven









INS-E611 6B DRSP (PEN-R, CRO-I, SXT-R) 4+
INS-E674 14 DRSP (PEN-R, CRO-I, SXT-R) 1+
INS-E676 14 DRSP (PEN-I, SXT-R) 1+
INS-E678 14 DRSP (PEN-I, SXT-R) 1+
INS-E683 9 V DRSP (PEN-I, SXT-R) 2+
INS-E684 14 PNSSP (PEN-I) 2+
ATCC 49619 19 F PNSSP (PEN-I) 3+
Abbreviations. INS: Instituto Nacional de Salud; CSF: Cerebro-Spinal fluid; DRSP:
Drug-Resistant S. pneumoniae; PNSSP: Penicillin-Non-Susceptible S. pneumoniae;
PEN: Penicillin; CRO: Ceftriaxone; SXT: Trimethoprim-sulfamethoxazole; CHL:
Chloramphenicol; R: Resistant; I: Intermediate; *Mouse virulence of 4+ means that
mice died during the assay, 3+: mice with systemic illness, 2+: mice with localized
sickness and 1+: mice without clinical signs of disease.
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At the selected time points, we euthanized the mice by
cervical dislocation, opened the thorax under aseptic
technique to remove both lungs in block (cutting at the
point of bronchial bifurcation from the trachea), homog-
enized it in 2.7 mL of sterile saline, and plated sequential
10-fold dilutions for colony counting (CFU/g). Both
lungs weighed in average 0.3 g. Control animals, unin-
fected but anesthetized and instilled with 50 μL sterile
normal saline, were used in all experiments. We checked
the animals every 6 hours during the survival experi-
ments and processed immediately any mouse found
dead. Animals fulfilling any of these criteria were hu-
manely euthanized: (a) inability to obtain feed or water,
or (b) moribund state or no response to gentle stimuli.
The data, expressed as bacterial counts in the lungs of
each animal (log10 CFU/g), were stored using Microsoft
Excel 2013 (Microsoft Corp., Seattle, WA, USA) and
analyzed and graphed in Prism 6.0 (GraphPad Software,
San Diego, CA, USA).
Development of the lethal and reproducible model of
pneumonia
For each strain of S. pneumoniae (E611, E674, E676,
E678, E683, E684, and ATCC 49619), two groups of neu-
tropenic mice received the bacterial inoculum without
or with mucin supplementation to test its impact on the
lethality and reproducibility of the model. When supple-
mented, the bacterial inoculum was mixed with porcine
mucin (M-1778; Sigma Chemical Company, St Louis,
MO) just before nasal instillation. For this instance, a
mucin stock solution (10% [wt/vol]) was diluted 1:1 with
the pneumococcal suspension in supplemented THB
with ~8 log10 CFU/mL prepared as describe above, for a
final mucin concentration of 5%.
Impact of neutrophils on the model
To assess the impact of neutrophils in the development
of the model we infected groups of PNSSP immunocom-
petent mice with each one of the seven S. pneumoniae
strains (E611, E674, E676, E678, E683, E684, and ATCC
49619) using the same conditions for inoculum preparation
and mucin supplementation described above. Animals were
sacrificed at 0, 14, 24, 38 and 120 hours for CFU count per
gram of lung.
Histopathology
We compared the morphological changes 38 h after
mice infection fixing both lungs with 10% buffered for-
malin and staining with hematoxylin and eosin. After
blind reading by a pathologist, samples of three different
groups of mice were compared: (a) mice inoculated only
with mucin (controls, not infected), (b) mice infected
with S. pneumoniae INS-E611 without mucin, or (c)mice infected with the same strain but supplementing
the inoculum with mucin.Statistical analysis
All data are presented as geometric mean ± SD. The net
bacterial growth (G) was defined as the change in bac-
terial density calculated as the difference in mean log10
CFU/g at the zenith (highest bacterial growth) and nadir
(lowest bacterial load in tissue) for the different strains.
Differences at zenith on bacterial burden in lungs of
mice infected with an optimized inoculum of pneumo-
cocci with or without mucin were analyzed by the
Mann–Whitney test [20]. Data were considered signifi-
cant when P values were <0.05 by the use of two-tailed
significance levels.Results
Strains and murine virulence
Table 1 summarizes the capsular serotypes, pattern of
antibiotic susceptibility, and murine virulence of each
strain studied in vivo without mucin enhancement. Des-
pite the fact that all 7 strains were encapsulated with al-
most the same capsular densities ranging from 1.029 to
1.034 [21], murine virulence varied widely among them.
Two out of 7 (29%) strains exhibited some degree of
virulence (≥3+) after 48 h of infection and 5 of 7 (71%)
induced minimal to no clinical changes (non-virulent
strains) after several passages in thighs.
Strain INS-E611 (PNSSP) exhibited the highest murine
systemic virulence, killing immunocompetent mice early
(<24 h after thigh infection) with dissemination to
distant organs after passes in vivo (data not shown).
According to these results, we selected INS-E611 as the
non-susceptible strain to standardize the optimized pneu-
monia model.
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neutropenic mice
Figure 1 illustrates the pulmonary bacterial load at dif-
ferent times in two independent experiments after nasal
instillation of S. pneumoniae INS-E611 (without mucin).
In both experiments, we used a previously standardized
methodology to produce a high quality culture that pre-
vents bacterial autolysis [17]. The inoculum per mouse
was 6.94 and 6.96 log10 CFU for experiments 1 and 2,
respectively. The dynamics of in vivo bacterial growth
were overlapped using the data from both experiments.
The nadir was detected at 12 h (5.3 ± 0.56 and 5.65 ±
0.48 log10 CFU/g, for experiments 1 and 2, respectively),
growth restarted at 14 h, and the zenith was reached
36 h after infection (7.42 ± 0.38 and 7.81 ± 0.14 log10
CFU/g, for experiments 1 and 2, respectively). The net
growth during the 24 hours spanning from nadir to zen-
ith (G12→36h) ranged from 2.11 to 2.16 log10 CFU/g. In
spite of this bacterial growth, all animals recovered and
were alive and healthy 120 h after infection; it correlated
with a marked reduction (1 log) in the number of bac-
teria per gram of lung at 38 h (6.50 ± 0.43 log10 CFU/g)
and an increment in the variance at 48 h (SD > 1.3 log10
CFU/g in both experiments), as expected when the
infection is being cleared. Additionally, the bacterial
burden in organs other than the lungs (i.e. blood and
spleen) was also highly variable (SD ranging from 0.54
to 1.04 log10 CFU/g) with a mean load of only 2.48 log10
CFU/g, close to the limit of detection (2.0 log10 CFU/g).
Therefore, the nasal instillation of a highly virulent
strain of PNSSP was followed by significant and repro-
ducible net growth in vivo, but all animals cleared theFigure 1 Reproducibility of the pneumonia model using an
optimized culture of S. pneumoniae. In vivo growth dynamics of
S. pneumoniae INS-E611 in neutropenic mice using an optimized
inoculum. Data from two independent experiments; the circles
represent the mean (three mice per time-point) and the error bars
the standard deviation.infection and recovered spontaneously within 48 h des-
pite being almost depleted of neutrophils (<100/μL) [19].
Development of the lethal model of pneumonia
Table 2 shows that addition of mucin to the optimized
inoculum of S. pneumoniae INS-E611 for nasal instilla-
tion resulted in continuous growth of bacteria; the nadir
occurred at 14 h (5.35 ± 0.53 log10 CFU/g) and the zen-
ith at 38 h (9.26 ± 0.19 log10 CFU/g). The net growth
during the 24 h period spanning from nadir to zenith
(G14→38h) was 3.91 log10 CFU/g, and mice mortality
reached 100% within the same period. Control mice in-
stilled with mucin without bacteria remained healthy
and had sterile lungs at 38 h.
The addition of mucin to the bacterial inoculum trans-
formed the pneumonia model from non-lethal (0%) to
uniformly lethal (100%), and it correlated with a statisti-
cally significant increase in the bacterial burden of the
lungs 38 h after infection (6.50 ± 0.43 without mucin vs.
9.26 ± 0.19 log10 CFU/g with mucin; P = 0.04 by Mann–
Whitney test).
Impact of neutrophils on the model
Fully immunocompetent mice spontaneously cleared the
infection 120 hours after inoculation with any of the
seven strains despite using the optimized inoculum sup-
plemented with mucin (Figure 2). It shows that neutro-
penia is essential for the development of a successful
model with PNSSP strains.
Pulmonary histopathology
Figure 3 shows the histological findings in the lungs of
the different groups of granulocytopenic mice sacrificed
38 h post-infection with S. pneumoniae INS-E611. With-
out mucin, mild changes were observed related to
lymphocytic interstitial and hemorrhagic pneumonitis
with some areas of atelectasis (panels a and b). In sharp
contrast, the addition of mucin to the inoculum led to
severe lung damage characterized by extensive septum
edema, necrosis, and destruction of the alveolar struc-
ture; lymphocyte and mononuclear cell infiltrate and
abundant bacteria accumulated within fibrin clots near
alveolar septa (panels c and d). The expected poly-
morphonuclear infiltrate and subsequent lung consoli-
dation of human pneumonia is not evident in this
model because profound granulocytopenia was in-
duced in the animals with cyclophosphamide [19].
Control mice nasally instilled with sterile broth and
mucin only showed slight histological changes compat-
ible with aspirational chemical pneumonitis without al-
veolar hemorrhage (non-specific lymphocytic interstitial
pneumonitis). These animals never exhibited clinical
signs of disease (Figure 3, panels e and f).
Table 2 Impact of inoculating bacteria without or with 5% porcine mucin in the model of pneumonia in neutropenic mice with diverse strains of penicillin non
susceptible Streptococcus pneumoniae (PNSSP)
Strain of Penicillin Non Susceptible Streptococcus pneumoniae
Parameter ATCC 49619 INS-E611 INS-E674 INS-E676* INS-E678* INS-E683 INS-E684
Inoculum preparation: Todd Hewitt















Inoculum (mean, log10 CFU/mouse) 7.12 6.34 6.95 6.78 6.46 6.79 6.28 6.20 6.53 6.53 6.71 6.61 7.00 6.25
Time to nadir (h) 14 14 14 14 14 14 ** ** ** ** 14 14 14 14
Time to zenith (h) 42 38 36 38 48 38 *** *** *** *** 36 38 48 38




6.32 ± 0.52 5.43 ±
0.39
5.35 ± 0.53 6.52 ±
0.65
7.34 ± 0.43 4.30 ±
0.36
3.97 ± 0.43 4.93 ±
0.06
6.02 ± 0.13 4.90 ±
0.17
5.70 ± 0.39 7.01 ±
0.72
6.73 ± 0.74




6.79 ± 0.44 7.58 ±
0.35
9.26 ± 0.19 8.70 ±
0.51
9.15 ± 0.34 5.09 ±
0.56
7.51 ± 0.18 6.68 ±
0.04
8.67 ± 0.28 7.77 ±
0.53
8.91 ± 0.75 9.59 ±
0.53
9.01 ± 0.52
Growth from nadir to zenith (mean) 2.19 0.47 2.15 3.91 2.18 1.63 — — — — 2.87 3.21 2.58 2.28
Growth from hour 14 to 38 (mean) 1.24 0.47 −0.43 3.91 1.89 1.63 0.79 3.54 1.75 2.65 1.83 3.21 1.94 2.28
Mouse Lethality (%) 0 100 0 100 67 100 0 100 0 100 0 100 100 100
Time to death (mean, h) All alive 64 All alive 52 56 52 All alive 44 All alive 44 All alive 59 61 51
Bacterial count after death from
pneumonia and sepsis (mean ± SD)
All alive 8.21 ± 0.51 All alive 8.37 ± 0.39 9.52 ±
0.01
9.00 ± 0.30 All alive 7.89 ± 0.43 All alive 8.92 ± 0.05 All alive 8.52 ± 0.62 8.22 ±
0.38
8.76 ± 0.04
*All PNSSP strains were used in at least in two separate experiments, except for E676 and E678, which were tested once.
**Time fixed at 14 h.











Figure 2 Impact of neutrophils on the model. In vivo growth
dynamics of seven strains of PNSSP using an optimized inoculum in
immune competent mice (normal neutrophil count). The animals
exhibited no clinical signs of disease and cleared the pneumococci
completely, indicating that neutropenia is a necessary requirement
for a successful infection model. The open symbols represent the
mean (at least three mice per time-point) and the error bars the
standard deviation. The net bacterial growth between the 14 h and
38 h (G14-38h) was included into the legend box for each strain.
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optimized cultures with mucin of different PNSSP strains
Table 2 summarizes the in vivo impact of inoculating
bacteria without or with 5% porcine mucin. Clearly, a le-
thal pneumonia model with active bacterial growth in
lungs was accurately established with all PNSSP strains
tested (E611, E674, E676, E678, E683, E684, and ATCC
49619) after the addition of mucin to the bacterial in-
oculum, independently of their serotype or intrinsic
murine virulence [17]. Besides, pneumococcal growth in
the lungs was steadier with mucin and mortality reached
100% between 42 to 86 h after infection due to very high
bacterial loads achieved in the lungs by the end of the
model (Figure 4). Without mucin (despite identically op-
timized culture conditions), there was a wide variation
in the time required to reach the zenith (36 to 48 h after
inoculation) and only 2 of the 7 strains (E674 and E684)
were lethal. All mice inoculated with 50 μL of sterile
THB with mucin were healthy during 10 days of
follow-up.
Discussion
Animal models are indispensable tools for the study of
infectious diseases and represent a link between in vitro
and in vivo situations. In this regard, the possible trans-
lation of the results to humans demands the proof of
“predictive validity”, meaning that reliability (which in-
volves repeatability and reproducibility) and relevance
(accuracy to predict the biological response) were deter-
mined during the standardization of the animal model
[22]. However, respiratory tract infection models in
mice using penicillin-resistant pneumococci strains fromhuman infections has been a challenge. In fact, there is
no evidence of predictive validity in the models used
since 1980. According to our in vivo data without mucin
(Figure 1), the high variability (SD > 1.3 log10 CFU/g at
48 h) on the bacterial load in lungs hampers the repeatabil-
ity and reproducibility of the non-optimized model. Our
findings with the non-optimized model are similar to those
reported by Beskid et al. [23] and Azoulay-Dupuis et. al.
[24], some of the most cited authors in this field.
Other pneumonia models by S. pneumoniae are avail-
able in the literature characterizing bacterial and host
factors of virulence or testing the efficacy of antimicro-
bials and vaccines [25]. In general, these models require
strains with capsular serotypes 2–6 because the other se-
rotypes lack murine virulence [9,21].
Here, we improved the mouse pneumonia model by
optimization of in vitro culture conditions and addition
of mucin to the nasal inoculum, establishing a uniformly
lethal infection. Additionally, the model was character-
ized by very high and steady bacterial counts in the
lungs that correlated with histopathological signs of in-
fection, even with strains belonging to serotypes 9V, 14,
and 19F, known for their low virulence against Mus
musculus.
Recently, we demonstrated the relevance of the pneu-
monia model in neutropenic mice to predict the biologic
response [26]. Since the host’s immune system enhances
significantly the efficacy of most antimicrobials, its elim-
ination is necessary to determine the intrinsic bacteri-
cidal activity in vivo [19,27].
Nungester et al. pioneered the use of mucin to induce
lethality to immunocompetent rats infected by intra-
tracheal instillation of a fully susceptible (serotype 3)
pneumococcus strain [12,28]. Using survival as outcome
and detailed histopathology, they described extensively
the role of mucin to enhance mortality. Our results
demonstrate that optimization of in vitro culture condi-
tions, mucin supplementation of the inoculum, and neu-
tropenia are required to induce progressive growth of
PNSSP in the lungs, and that success is achieved inde-
pendently of the intrinsic virulence of the strain, its
capsular serotype or resistance to penicillin. Although
capsular type and antibiotic susceptibility are factors that
determine the virulence of pneumococci [16,21,29,30],
our optimized inoculum prevented their interference
with the growth of pneumococci in vivo. Moreover, our
method induces a degree of in vivo replication of S.
pneumoniae that exceeds significantly the mean bacterial
burden reported by other authors [14,31], with the
additional advantages of low variability and short dur-
ation of the model (38 h). These characteristics are
essential to ensure the reliability and relevance of the
model and indispensable to prevent unnecessary suf-
fering to the animals [22].
Figure 3 Histopathological finding in lungs of mice infected with S. pneumoniae (with or without mucin) or instilled with sterile mucin.
Lung biopsies stained with hematoxylin-eosin and observed under optic microscopy with magnification of x4 (panels a and c), x10 (panels b and
d) and x40 (panels e and f). Panels a and b correspond to mice infected with an inoculum of S. pneumoniae INS-E611 grown in Todd-Hewitt
broth (THB) without mucin, panels c and d correspond to animals infected with mucin-supplemented inoculum and panels e and f show the
lungs from uninfected mice instilled with sterile mucin. Abbreviations: necrosis (N), atelectasis (T), Gram positive bacteria (B), edema (E) and
lymphocytes (L).
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covered and protected by mucus. Mucins are a family of
large molecular weight glycoproteins with a high content
of clustered oligosaccharides with O-glycosidic links to
tandem repeat peptides rich in threonine, serine, and
proline; additionally, they are major constituents of the
mucus layer [32]. There are two distinct classes of human
mucin, the secreted gel-forming (MUC2, MUC5AC,
MUC5B, and MUC7) and the membrane-associated
mucins, also called MAMs (MUC1, MUC3A, MUC3B,MUC4, MUC11, MUC12, MUC16) [33,34]. Each one of
the human mucins has a related mucin in mice (named
Muc instead of MUC to differentiate between species)
[34]. Secreted mucins are produced by the goblet cells and
serve to cover, hydrate and sweep away trapped foreign
material from the uppermost coating of the epithelium.
The MAMs are anchored to the apical epithelium cell
membrane by single transmembrane domains, and serve
as a glycocalyx barrier that prevents microbial adherence
to airway epithelium. Most organs synthesize more than
Figure 4 Inter-strain reproducibility of pneumonia model
using optimized culture condition with mucin. In vivo growth
dynamics of diverse strains of penicillin-non susceptible S.
pneumoniae (INS-E674, E683, E684 and ATCC 49619) using an
early log-phase inoculum supplemented with mucin (data from
at least two different experiments). INS-676 and 678 (marked with
an asterisk in the legend) were tested in one single experiment.
The vertical dotted line indicates the time when a group of
animals was sacrificed for bacterial counting in the lungs. Data
after the line was obtained from animals left for survival assessment
(all dead by the end of the experiment).
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inate in a particular organ [32]. Previously, Adler et al.
described that cell-free filtrates from broth cultures of
Pseudomonas aeruginosa, Haemophilus influenzae and
Streptococcus pneumoniae stimulate secretion of glyco-
conjugates by explants of guinea pig trachea [35]. In fact,
they found that the extracellular product of S. pneumoniae
that stimulates mucin secretion is a protein with a mo-
lecular weight ranging from 100,000 to 300,000 Da, and
concluded that “the bacteria themselves may contribute to
local manifestations” [35]. Here, we used one of the se-
creted mucins (purified porcin gastric mucin, pPGM type
III, Sigma) to mimic the first action of the virulent strains
exposed to the airway epithelia, that is, to secrete an extra-
cellular protein with stimulatory effects on mucin produc-
tion. Although the serine, threonine and proline repeat
sequences of each MUC gene are species-specific, the cys-
rich regions can be compared between different species to
identify some similarity [36]. Thus, porcine gastric mucin
(PGM), one of the most characterized mucins, has two
fully sequenced clones (PGM-2A and PGM-9B) with func-
tion and structure related to the human mucins. More-
over, the arrangement of PGM-2A is identical with that
reported for human intestinal mucin gene MUC2, while
PGM-9B is related with MUC5AC [37,38].
Mucin supplementation works even for pneumococ-
cal serotypes lacking murine virulence; the data suggest
that mucin turns these strains lethal. This situation
mirrors the clinical scenario in which viral infectionslike influenza predispose to secondary bacterial super-
infections [39,40]. During the inflammatory response to
viral infection, gene expression is upregulated for many
molecules including the secreted mucins. Hypersecre-
tion of mucin, increased viscoelasticity of mucus and
decreased ciliary function in patients with viral respira-
tory infections or chronic diseases like asthma, COPD,
and cystic fibrosis, can lead to airway obstruction and
promote persistence of trapped pathogens in the air-
ways [41]. In addition, epithelial mucins interact with
several other respiratory pathogens including Pseudo-
monas aeruginosa, Staphylococcus aureus, Haemophilus
influenzae and Streptococcus pneumoniae [42]. Bound
pathogens persist in the airway and may initiate an inflam-
matory response mediated by virulence enhancement fac-
tors regulated by mucin, like the neuraminidase A [43].
Optimization of in vitro culture conditions was rele-
vant for the success of the pneumococcal model. Recently,
similar findings with enterococci [44] and coagulase-
negative staphylococci have been reported [45]. The proto-
col specifying the optimal culture conditions required to
obtain large numbers of young and healthy PNSSP cells in
the early phase of growth without untimely activation of
autolysis is already published [17]. Although little attention
has been given to the role of in vitro conditions for bacterial
growth in recent reviews of pneumococcal pneumonia
models [5,10], scant bacterial growth (<1 log10 CFU/g) with
huge variance (SD > 1 log10 CFU/g) are common character-
istics of classic models of pneumococcal pneumonia
[6,16,46,47]. Furthermore, models using non-optimized in-
ocula of pneumococci in late-growth phase are proposed as
protocols [25]. The methods and the data exposed here
provide a simple mouse model of pneumococcal pneumo-
nia with markedly improved reliability and relevance to de-
termine the pharmacodynamics of antibiotics [15].Conclusions
Optimization of culture and inoculum conditions of
PNSSP allows the induction of lethal pneumonia after
nasal instillation of diverse strains to neutropenic
mice, independently of the pneumococcal murine
virulence. This model is suitable, reliable and reprodu-
cible for anti-infective pharmacology research.
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